Gastroenterology
Volume 128, Issue 7 , Pages 1805-1811 , June 2005

Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study

  • Gunnar Järnerot

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Örebro University Hospital, Örebro, Sweden
    • Corresponding Author InformationAddress requests for reprints to: Gunnar Järnerot, MD, PhD, FRCP, Department of Medicine, Division of Gastroenterology, Örebro University Hospital, S-701 85 Örebro, Sweden.
    • ,
  • Erik Hertervig

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Lund University Hospital, Lund, Sweden
    • ,
  • Ingalill Friis-Liby

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Sahlgrenska University Hospital, Gothenburg, Sweden
    • ,
  • Lars Blomquist

      Affiliations

    • Department of Gastroenterology and Hepatology, Karolinska University Hospital, Stockholm, Sweden
    • ,
  • Per Karlén

      Affiliations

    • Department of Medicine, Division of Gastroenterology, South Hospital, Stockholm, Sweden
    • ,
  • Christer Grännö

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Ryhov Hospital, Jönköping, Sweden
    • ,
  • Mogens Vilien

      Affiliations

    • Department of Medicine, Division of Gastroenterology, West Zealand Hospital, Slagelse, Denmark
    • ,
  • Magnus Ström

      Affiliations

    • Department of Molecular and Clinical Medicine, Division of Gastroenterology and Hepatology, Faculty of Health Sciences, Linköping, Sweden
    • ,
  • Åke Danielsson

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Umeå University Hospital, Umeå, Sweden
    • ,
  • Hans Verbaan

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Malmö General University Hospital, Malmö, Sweden
    • ,
  • Per M. Hellström

      Affiliations

    • Department of Gastroenterology and Hepatology, Karolinska University Hospital, Stockholm, Sweden
    • ,
  • Anders Magnuson

      Affiliations

    • Unit of Statistics and Epidemiology, Centre for Clinical Research, Örebro University Hospital, Örebro, Sweden
    • ,
  • Bengt Curman

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Örebro University Hospital, Örebro, Sweden

Received 9 November 2004 ,Accepted 23 February 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by the Swedish Federation of County Councils, Örebro County Research Foundation, Schering-Plough AB, Sweden, Clinical Research Centre, Örebro University Hospital, the Medical Research Council of Southeast Sweden, Foundation of Medical Science Region 3, Denmark (Grant 2-47-19-02), and participating hospitals (infliximab/placebo).

PII: S0016-5085(05)00384-7

doi: 10.1053/j.gastro.2005.03.003

Gastroenterology
Volume 128, Issue 7 , Pages 1805-1811 , June 2005

Article Tools

* Image Usage & Resolution